HEDIS glycemic goal achieved using control-IQ Technology.

OBJECTIVES

This analysis evaluated changes in glucose management indicator (GMI) at 12 months from baseline hemoglobin A1c (HbA1c)-which are both used interchangeably in the Healthcare Effectiveness Data and Information Set (HEDIS) quality measures for glycemic status-in individuals with type 1 diabetes (T1D) who switched from multiple daily insulin injections (MDI) to Control-IQ technology, an automated insulin delivery (AID) therapy.

STUDY

DESIGN

US-based retrospective analysis that used data from the Tandem Diabetes Care, Inc t:connect web application and customer relationship management database.

METHODS

Inclusion criteria were having had prior treatment with MDI, having started Control-IQ at least 1 year prior to the study end date, having a most recent recorded baseline HbA1c measurement within 6 months prior to AID initiation, and having at least 70% continuous glucose monitoring use during the 12-month postinitiation period. The primary outcome was the change in number and proportion of individuals who met the HEDIS quality measure (HbA1c or GMI of < 8% [control] or > 9.0% [poor control]) and American Diabetes Association (ADA) glycemic target (< 7%) according to payer type (commercial, Medicaid, Medicare) during the 12-month observation.

RESULTS

The analysis included 12,522 individuals with T1D. Following AID initiation, the number and proportion of individuals who met the HEDIS quality standard increased from 6205 (49.6%) to 11,632 (92.9%) at 12 months (∆ = 87.5%). Similar improvements were observed among those who achieved less than 7% GMI. Within all payer groups, the number of patients with baseline HbA 1c levels greater than 9% decreased from 3431 to 15 (∆ = -99.6%).

CONCLUSIONS

A greater proportion of individuals can achieve the HEDIS and ADA target goals for glycemic status with Control-IQ use compared with MDI use across all payer types.